Skip to content

Evaluation of the Quality of Life After a Multidisciplinary Auditory Rehabilitation Program

Evaluation of the Quality of Life After a Multidisciplinary Auditory Rehabilitation Program

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05228769
Acronym
EQUAPRAP
Enrollment
25
Registered
2022-02-08
Start date
2021-12-01
Completion date
2023-03-31
Last updated
2023-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Deafness

Brief summary

In 2008, the Handicap-Santé survey counted 10 million people with hearing difficulties in France, i.e. 16% of the national population. For 5.4 million of these people, the hearing limitations considered to be moderate to total, are likely to have repercussions on their daily life. In 2010, 600,000 people with hearing loss wore hearing aids, including 360,000 with very severe to total limitations who were unable to follow a conversation with others. Hearing loss can impact hearing skills (comprehension in noisy environments or with multiple speakers) and be a source of cognitive decline. It can also limit the quality of exchanges, communication and information taking. Several studies have shown that hearing loss can also have a negative effect on quality of life, psychological well-being, personal fulfillment, social relationships and can lead to social isolation, depression and/or anxiety. Currently, the treatment of people with hearing loss is often limited to hearing aids from a hearing aid specialist. Hearing rehabilitation and lip-reading training with a speech therapist may be offered at a later stage. However, many people who have been fitted with a hearing aid describe a decrease in their quality of life despite the fitting. Current treatment seems to deal mainly with auditory-cognitive problems. To date, no multidisciplinary rehabilitation services seem to be offered in France to take into account the other consequences of this condition: anxiety, depression, and limitations in social participation.

Interventions

None listed

Sponsors

Sainte-Marie Hospital
CollaboratorUNKNOWN
Fondation Hôpital Saint-Joseph
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients whose age ≥ 18 years * Patients with acquired hearing loss (mild, moderate, severe or profound) * Patients with hearing aids * Patients participating in a complete rehabilitation program * Patients who master the French language

Exclusion criteria

* Patients with proven cognitive impairment * Implanted patients * Patients under guardianship or curatorship * Patients deprived of liberty * Patients under court protection * Interruption of the rehabilitation program before a minimum of 6 half-days of HDJ * Patients objecting to the use of their data for this research

Design outcomes

Primary

MeasureTime frameDescription
Impact of multidisciplinary rehabilitation on the quality of life of adults with hearing aidsMonth 1This outcome corresponds to the Change in quality of life measured with the ERSA scale before and after rehabilitation.

Secondary

MeasureTime frameDescription
Patient profile of ageMonth 1This outcome corresponds to the number of age categories
Patient profile of type of hearing lossMonth 1This outcome corresponds to the number of type of hearing loss.
Patient profile of severityMonth 1This outcome corresponds to the type of severity.
Quality of life of patientsMonth 1This outcome corresponds to the overall quality of life, personal life, social life and work life of the assessment of the impact of deafness in adults. is a self-administered questionnaire. It is divided into 4 domains, each comprising 5 questions graded from 1 to 10. The questions are simple, and formulated so patients will answer according to how they feel at the actual time of the session.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026